New drug combo shows promise against deadly thyroid cancer
NCT ID NCT05696548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing a combination of two drugs, nivolumab and lenvatinib, in 51 people with anaplastic thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors. Anaplastic thyroid cancer is rare and fast-growing, so finding effective treatments is urgent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option for a rare and aggressive thyroid cancer that is currently hard to treat.
What could go wrong
This is a small, early-phase trial with only 51 participants. The treatment may cause significant side effects, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681, Japan
-
Hokkaido University Hospital
Hokkaido, Hokkaido, 060-8648, Japan
-
Hyogo Cancer Center
Akashi, Hyōgo, 673-8558, Japan
-
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
-
National Cancer Center Hospital
Tokyo, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Nippon Medical School Hospital
Tokyo, Tokyo, 113-8603, Japan
-
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
-
Yokohama City University Hospital
Yokohama, Kanagawa, 236-0004, Japan